Malta - English - Medicines Authority

sanofi malta limited - dimeticone; aluminium hydroxide; magnesium hydroxide - chewable tablet - dimeticone 25 mg; aluminium hydroxide 200 mg; magnesium hydroxide 200 mg - drugs for acid related disorders

Malta - English - Medicines Authority

sanofi malta limited - dimeticone; aluminium hydroxide; magnesium hydroxide - oral suspension - dimeticone 25 mg; aluminium hydroxide 114 mg; magnesium hydroxide 200 mg - drugs for acid related disorders

Malta - English - Medicines Authority

sanofi s.r.l viale l. bodio, 37/b 20158, milan, italy - dimeticone, aluminium oxide, hydrated, magnesium hydroxide - chewable tablet - dimeticone 25 milligram(s) ; aluminium oxide, hydrated 200 milligram(s) ; magnesium hydroxide 200 milligram(s) - drugs for acid related disorders

Malta - English - Medicines Authority

opella healthcare france sas t/a sanofi 157 avenue charles de gaulle, 92200 neuilly-sur-seine , france - dimeticone, aluminium oxide, hydrated, magnesium hydroxide - chewable tablet - dimeticone 25 mg aluminium oxide, hydrated 200 mg magnesium hydroxide 200 mg - drugs for acid related disorders

Malta - English - Medicines Authority

wallace manufacturing chemists limited - dimethicone, activated, aluminium hydroxide, magnesium hydroxide - oral suspension - dimethicone, activated 25 milligram(s) ; aluminium hydroxide 220 milligram(s) ; magnesium hydroxide 200 milligram(s) - drugs for functional gastrointestinal disorders

Panama - English - Ministerio de Salud (Dirección Nacional de Farmacia Y Drogas)

laboratorios compaÑÍa farmacÉutica l.c., s.a. - dimeticona - dimeticona....0.75g

Ireland - English - HPRA (Health Products Regulatory Authority)

sanofi-aventis ireland limited t/a sanofi - aluminium oxide, hydrated ph. eur; magnesium hydroxide ph. eur.; dimeticone ph. eur. (as simeticone ph. eur.) - chewable tablet - 200mg/200mg/25 milligram(s) - antacids with antiflatulents; ordinary salt combinations and antiflatulents

Australia - English - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - esomeprazole magnesium dihydrate, quantity: 21.69 mg - capsule, enteric - excipient ingredients: methacrylic acid - ethyl acrylate copolymer (1:1); triethyl citrate; titanium dioxide; mannitol; hypromellose; gelatin; stearoyl macrogolglycerides; maize starch; polysorbate 80; purified talc; iron oxide yellow; sucrose; diacetylated monoglycerides; purified water; dimeticone 350; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - gastro-oesophageal reflux disease (gord),? treatment of erosive reflux oesophagitis,? long-term management of patients with healed oesophagitis to prevent relapse,? symptomatic treatment of gastro-oesophageal reflux disease (gord),patients requiring nsaid therapy,? short-term treatment of upper gastrointestinal symptoms associated with non-steroidal anti-inflammatory drug nsaid (non-selective and cox-2 selective) therapy.,? healing of gastric ulcers associated with non-steroidal anti-inflammatory,drug nsaid (non-selective and cox-2 selective) therapy,? prevention of gastric and duodenal ulcers associated with non-steroidal anti inflammatory drug nsaid (non-selective and cox-2 selective) therapy in patients at risk.,prevention of rebleeding of gastric or duodenal ulcers following treatment with iv esomeprazole solution by intravenous infusion.,pathological hypersecretory conditions including zollinger-ellison syndrome and idiopathic hypersecretion,in combination with appropriate antibiotics for:,? healing of duodenal ulcer associated with helicobacter pylori,? eradication of helicobacter pylori in patients with active or healed peptic ulcer

Australia - English - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - esomeprazole magnesium dihydrate, quantity: 43.37 mg - capsule, enteric - excipient ingredients: maize starch; dimeticone 350; gelatin; purified water; hypromellose; sucrose; methacrylic acid - ethyl acrylate copolymer (1:1); titanium dioxide; polysorbate 80; triethyl citrate; purified talc; iron oxide yellow; diacetylated monoglycerides; mannitol; stearoyl macrogolglycerides; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - gastro-oesophageal reflux disease (gord),? treatment of erosive reflux oesophagitis,? long-term management of patients with healed oesophagitis to prevent relapse,? symptomatic treatment of gastro-oesophageal reflux disease (gord),patients requiring nsaid therapy,? short-term treatment of upper gastrointestinal symptoms associated with non-steroidal anti-inflammatory drug nsaid (non-selective and cox-2 selective) therapy.,? healing of gastric ulcers associated with non-steroidal anti-inflammatory,drug nsaid (non-selective and cox-2 selective) therapy,? prevention of gastric and duodenal ulcers associated with non-steroidal anti inflammatory drug nsaid (non-selective and cox-2 selective) therapy in patients at risk.,prevention of rebleeding of gastric or duodenal ulcers following treatment with iv esomeprazole solution by intravenous infusion.,pathological hypersecretory conditions including zollinger-ellison syndrome and idiopathic hypersecretion,in combination with appropriate antibiotics for:,? healing of duodenal ulcer associated with helicobacter pylori,? eradication of helicobacter pylori in patients with active or healed peptic ulcer

Ireland - English - HPRA (Health Products Regulatory Authority)

opella healthcare france sas t/a sanofi - aluminium oxide, hydrated ph. eur; magnesium hydroxide ph. eur.; dimeticone ph. eur. (as simeticone ph. eur.) - chewable tablet - 200mg/200mg/25 milligram(s) - antacids with antiflatulents; ordinary salt combinations and antiflatulents